Skip navigation

Rethinking the Lifeline

Does the commercial support system — as it exists today — inevitably compromise CME's independence? That's the question the Accreditation Council for CME will explore over the next year as it conducts its first-ever big-picture review of the funding process. It will examine a range of options, from leaving the system intact, to setting up a centralized grants repository, to limiting — or even prohibiting — pharmaceutical industry funding of CME. Since drug companies funnel about $1 billion

Register to view the full article

Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish